Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Parachuri, Nikulaa
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Saboo, Bharat
Tripathi, Hridaya Nath
Kuppermann, Baruch D.
Bandello, Francesco http://orcid.org/0000-0003-3238-9682
Article History
Received: 9 July 2021
Revised: 21 July 2021
Accepted: 30 July 2021
First Online: 9 August 2021
Competing interests
: AS: CONSULTANT: for Novartis, Allergan, Bayer and Intas. BDK: CLINICAL RESEARCH: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; CONSULTANT: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. BDK acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. NK: None. NP: None. BS: None. HNT: None.